Justin Gainor

Citado por

	Total	Desde 2019
Citas	39584	29006
Índice h	82	75
Índice i10	207	196

7000

3500

1750

5250

2012201320142015201620172018201920202021202220232024209 277 514 971 2031 2763 3218 3794 5063 6423 5908 5659 1968

Acceso público

Ver todo

119 artículos

9 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

subba digumarthyMassachusetts General HospitalDirección de correo verificada de partners.org
Aaron HataMassachusetts General HospitalDirección de correo verificada de mgh.harvard.edu
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer CenterDirección de correo verificada de mdanderson.org
Lecia V SequistProfessor of Medicine, Harvard Medical School and Massachusetts General HospitalDirección de correo verificada de partners.org
Matthew HellmannMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Joe LennerzMassachusetts General Hospital/Harvard Medical SchoolDirección de correo verificada de partners.org
luc fribouletGustave Roussy Université Paris SaclayDirección de correo verificada de gustaveroussy.fr
Sai-Hong Ignatius OuUniversity of California IrvineDirección de correo verificada de uci.edu
Scott J AntoniaDirección de correo verificada de duke.edu
Ryan SullivanMassachusetts General HospitalDirección de correo verificada de mgh.harvard.edu
Benjamin SolomonMedical Oncologist, Peter MacCallum Cancer CentreDirección de correo verificada de petermac.org
Ryohei KatayamaJapanese Foundation for Cancer ResearchDirección de correo verificada de jfcr.or.jp
Robert C. Doebele, MD, PhDUniversity of Colorado, Anschutz Medical CampusDirección de correo verificada de cuanschutz.edu
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterDirección de correo verificada de MSKCC.org
Wilfried EberhardtInnere Klinik (Tumorforschung), University of Duisburg-EssenDirección de correo verificada de uni-duisburg-essen.de
Paul BaasDepartment of Thoracic Oncology, Netherlands Cancer InstituteDirección de correo verificada de nki.nl
Michael LanutiAssociate Professor of Surgery, Harvard Medical SchoolDirección de correo verificada de partners.org
Stephen V. LiuGeorgetown UniversityDirección de correo verificada de gunet.georgetown.edu
Daniel SW TanNational Cancer Centre SingaporeDirección de correo verificada de nccs.com.sg
Alexander DrilonMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org

Seguir

Justin Gainor

Director, Center for Thoracic Cancers, Massachusetts General Hospital

Dirección de correo verificada de partners.org

Lung cancer targeted therapy thoracic oncology immunotherapy


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015	8809	2015
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020	1827	2020
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1253	2018
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018	1230	2018
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011	1135	2011
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016	1112	2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016	1101	2016
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014	907	2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014	787	2014
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020	668	2020
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ... The Lancet Oncology 18 (12), 1590-1599, 2017	651	2017
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013	635	2013
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992, 2019	539	2019
Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016	525	2016
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial CA Shu, JF Gainor, MM Awad, C Chiuzan, CM Grigg, A Pabani, ... The Lancet Oncology 21 (6), 786-795, 2020	484	2020
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011	470	2011
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015	464	2015
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018	459	2018
Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013	453	2013
A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016	410	2016

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores